Abstract
Recent technological advancements have been made in controlled oral drug delivery systems by overcoming physiological difficulties, such as short gastric residence time and highly variable gastric emptying time. Gastroretentive dosage forms have been designed over the past three decades to overcome these difficulties. Several technical approaches are currently utilised in the prolongation of gastric residence time, including high-density, swelling and expanding, polymeric mucoadhesive, ion-exchange, raft forming, magnetic and floating drug delivery systems, as well as other delayed gastric emptying devices. Gastroretentive drug delivery systems have been shown to have better efficacy in controlling the release rate for drugs with site-specific absorption. In this review, the concepts of gastric emptying and absorption windows, and current technological developments in gastroretentive drug delivery systems are discussed, including their advantages and disadvantages, along with various evaluation techniques and marketed products for gastroretentive drug delivery. Bioadhesive, superporous hydrogel, floating and expanding systems show the most promising potential for achieving the goal of gastroretention. A superporous hydrogel drug delivery system is currently the most reliable, convenient and advantageous technique available that assures prolonged gastric residence time.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Garg S, Sharma S. Gastroretentive drug delivery systems [online]. Available from URL: http://www.touchbriefings.com/pdf/17/pt031_p_garg.pdf [Accessed 2005 May 20]
Chawla G, Gupta P, Koradia V, et al. Gastroretention: a means to address regional variability in intestinal drug absorption. Pharm Tech 2003 July; 27 (7): 50–68
Lee TWY, Robinson JR. Controlled release drug delivery system. In: Gennaro AL, editor. Remington: the science and practice of pharmacy. Philadelphia (PA): Philadelphia College of Pharmacy and Science, 2000: 903–29
Chien YW. Oral drug delivery and delivery systems. In: Chien YW, editor. Novel drug delivery systems. New York: Marcel Dekker, 1992: 139–96
Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 1996; 136: 117–39
Vyas SP, Khar RK. Gastroretentive systems. In: Vyas SP, Khar RK, editors. Controlled drug delivery: concepts and advances. 1st ed. New Delhi: Vallabh Prakashan, 2005: 196–218
Ashford M. The gastrointestinal tract physiology and drug absorption. In: Aulton ME, editor. Pharmaceutics: the science of dosage form design. 2nd ed. New York: Churchill Livingstone, 2002: 217–27
Gupta PK, Robinson JR. Oral controlled-release delivery. In: Kydonieus A, editor. Treatise on controlled drug delivery. New York: Marcel Dekker, 1992: 255–310
Tayade P. Gastroretentive drugs: a review, 2003 [online]. Available from URL: http://www.expresspharmapulse.com/20030417/ndds1.shtml [Accessed 2005 Mar 18]
Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Rel 2003; 90: 143–62
Hejazi R, Amiji M. Stomach specific anti H. pylori therapy: preparation and characterization of tetracycline of a floating multiple-unit capsule, a high density loaded chitosan microspheres. Int J Pharm 2002; 235: 87–94
Sawicki W. Pharmacokinetics of verapamil and nor verapamil from controlled release floating pellets in humans. Eur J Pharm Biopharm 2002; 53: 29–35
Nim KH, Singh BN. Drug delivery: oral route. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. Vol 1._2nd ed. New York: Marcel Dekker, 2000: 886–907
Boulton DW, Fawcett JP, et al. Enantioselective disposition of albuterol in humans. Clin Rev Allergy Immunol 1996; 14: 115–38
Hoter D, Dreessman JB. Influence of physiochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Del Rev 1987; 25 (1): 3–14
Sato Y, Kawashima Y, Takeuchi H, et al. In vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers. J Control Rel 2003; 93 (1): 39–47
Groning R. Control of release and biological availability of drugs: investigations into the renal elimination of nitrofurantoin. Int J Pharm 1981; 8: 175–81
Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm 2000; 210 (1): 45–9
Dave BS, Amin AV, Patel MM. Gastroretentive drug delivery system of ranitidine HCl formulation and in vitro evaluation. AAPS Pharm Sci Tech 2004; 5 (2) 34: 1–10 [online]. Available from URL: http://www.aaps.pharm.sci.tech.org/ [Ac-cessed 2005 Apr 10]
Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release kinetics. DDIP 2000; 26 (9): 965–9
Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy: II, gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm Dev Technol 2003; 8 (3): 253–62
Fell JT. Targeting of drugs and delivery systems to specific sites in the gastrointes- tinal tract. J Anat 1996; 189: 517–9
Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci 1994; 83 (2): 239–45
Bardonnet PL, Faivre V, Pugh WJ, et al. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Rel 2006; 111: 1–18
Hwang SJ, Park H, Park K. Gastric retentive drug delivery systems. Crit Rev Ther Drug Carr Sys. 1998; 15 (3): 243–84
Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Rel 2000; 63 (1-2): 235–59
Deshpande AA, Rhodes CT, Shah NH, et al. Controlled release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm 1996; 22 (6): 531–9
Ali J, Ahuja A, Khar RK. Controlled drug delivery system. In: Ali J, Ahuja A, Khar RK, editors, Dosage form design. 1st ed. New Delhi: Birla Publications, 2005: 168–229
Arora S, Ali J, Ahuja A, et al. Floating drug delivery systems: a review. AAPS Pharm Sci Tech 2005; 06 (03): E372–E390 [online]. Available from URL: http:/ /www.aaps.pharm.sci.tech.org/ [Accessed 2005 Sep 20]
Caldwell LJ, Gardner CR, Cargill RC, inventors. Drug delivery device which can be retained in the stomach for a controlled period of time. Merck & Co., Inc., assignee. US Patent no. 4,735,804._1988 Apr 5
Akiyama Y, Nagahara N, Nara E. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. J Pharm Pharmacol 1998; 50 (2): 159–66
Reddy LH, Murthy RS. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carr Syst 2002 19 (6): 553–85
Hoffman A, David S, Lavy E, et al. Pharmacokinetics and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004; 277: 141–53
Chawla G, Gupta P, Bansal AK. Gastroretentive drug delivery system. In: Jain NK, editor. Progress in controlled and novel drug delivery systems. 1st ed. New Delhi: CBS publishers, 2004: 79–81
Waergh A, Allison G. The digestive system. In: Waugh A, editor. Rose & Wilson anatomy and physiology in health and illness. 9th ed. Philadelphia (PA): Springer, 2005: 325–38
Chaurasia BD. Abdominal part of oesophagus and stomach. In: Singh I, editor. Human anatomy, regional and applied. 3rd ed. New Delhi: CBS publishers, 2000, 206–11
Feldman M, Barnett C. Fasting gastric pH and its relationship to true hypochlorhydria in humans. Dig Dis Sci 1991; 36: 866–9
Benini L, Brighenti F, Castellani G, et al. Gastric-emptying of solids is markedly delayed when meals are fried. Dig Dis Sci 1994; 39: 2288–94
Ganong WF. Regulation of gastrointestinal function. In: Review of medical physiology. 22nd ed. San Francisco (CA): McGraw-Hill, 2005: 479–512
Read NW, Sugden K. Gastrointestinal dynamics and pharmacology for the optimum design of controlled release oral dosage form. Crit Rev Ther Drug Carrier Syst 1987; 4 Suppl. 3: 221–63
Guyton AC, Hall JE. General principles of gastrointestinal function: motility, nervous control and blood circulation. In: Guyton AC, Hall JB, editors. Text book of medical physiology. 10th ed. Philadelphia (PA): WB Saunders, 2004: 718–26
Washington N, Washington C, Millon CG. The digestion and absorption of food. In: Washington N, Washington C, Millon CG, editors. Physiological barriers to drug absorption. 2nd ed. New York: Taylor and Francis, 2005: 75–103
Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991; 8 (3): 360–4
Rocca DJG, Omidian H, Shah K. Progress in gastroretentive drug delivery systems. Business Briefing 2003: 152–155 [online]. Available from URL: http://www.b-briefings.com/ [Accessed 2005 Jul 3]
Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carr Syst 2003; 20 (6): 459–97
Frieri G, Petris GD, Aggio A, et al. Gastric and duodenal juxtamucosal pH and Helicobacter pylori. Digestion 1995; 56 (2): 107–10
Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol 1990; 42 (7): 500–1
Mazer N, Abisch E, Gfeller JC, et al. Intragastric gastrointestinal behavior and absorption kinetics of a normal and ‘floating’ modified-release capsule of isradipine under fasted and fed conditions. J Pharm Sci 1988; 8: 647–57
Clarke GM, Newton JM, Short MD. Gastrointestinal transit of pellets of differing size and density. Int J Pharm 1993; 100 (1-3): 81–92
Meyer JH, Dressman J, Fink AS, et al. Effect of size and density on gastric emptying of indigestible solids. Gastroenterology 1985; 88: 1502–7
Goldschmiedt M, Barnett CC, Schwarz BE. Effect of age on gastric acid secretion and serum gastric concentrations in healthy men and women. Gastroenterology 1991; 101: 977–90
Renwick AG, Ahsan CH, Challensor VF, et al. The influence of posture on the pharmacokinetics of orally administered nifedipine. Br J Clin Pharmacol 1992; 34: 332–6
Bennett CE, Herdy JG, Wilson LG. The influence of posture on gastric emptying of antacids. Int J Pharm 1984; 21: 341–7
Timmermans J, Andre JM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci 1994; 83: 18–24
Timmermans J, Moes AJ. How well do floating dosage forms float? Int J Pharm 1990; 62 (3): 207–16
Peppas NA, Bures P, Leobandung W, et al. Hydrogels in pharmaceutical formulations. Eur J Pharm Sci 2000; 50: 27–46
Steingoetter A, Kunz P, Weishaupt D, et al. Analysis of the meal dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 18 (7): 713–20
Fell JT, Whitehead L, Collett JH. Prolonged gastric retention using floating dosage forms. PharmTech 2000; 24 (3): 90
Riner JL, Byford RL, Stratton LG, et al. Influence of density and location on degradation of sustained-release boluses given to cattle. Am J Vet Res 1982; 43 (11): 2028–30
Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellet systems of varying density. Int J Pharm 1995; 114 (1): 1–11
Riner JL, Byford RL, Stratton LG, et al. Influence of density and location on degradation of sustained-release boluses given to cattle. Am J Vet Res 1982; 43 (11): 2028–30
Lehr CM, Hass J. Developments in the area of bioadhesive drug delivery systems. Expert Opin Biol Ther 2002; 2: 287–98
Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Del Rev 1998; 34: 191–219
Lehr CM, Bouwstra JA, Schachat EH, et al. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992; 78: 43–8
Sinha VR, Singla AK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004; 274 (1–2): 1–33
Park K, Robinson JR. Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion. Int J Pharm 1984; 19 (1): 107–27
Haas J, Lehr CM. Developments in the area of bioadhesive drug delivery systems. Expert Opin Biol Ther 2002; 2 (3): 287–98
Shivakumar HG, Gowda DV, Pramodkumar TM. Floating controlled drug delivery systems for prolonged gastric residence: a review. Ind J Pharm Edu 2004; 38 (4): 172–80
Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002; 7 Suppl. 10: 569–79
Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Rel 2003; 90: 143–62
Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002; 7 (10): 569–79
Moes AJ. gastric retention systems for oral drug delivery. Business Briefing 2003; 157-159 [online]. Available from URL: http://www.bbriefings.com/ [Accessed 2005 Jun 13]
Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing 2003; 160–66 [online]. Available from URL: http://www.bbriefings.com/ [Accessed 2005 Jun 13]
Atyabi F, Sharma HL, Sharma H, et al. Controlled drug release from coated floating ion exchange resin beads. J Control Rel 1996; 42 (1): 25–8
Atyabi F, Sharma HL, Mohammad HAH, et al. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J Control Rel 1996; 42 (2): 105–13
Burton S, Washington N, Steele RJC. Intragastric distribution of ion-exchange resins: a drug delivery system for the topical treatment of the gastric mucosa. J Pharm Pharmacol 1995; 47: 901–6
Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv 2003; 10 (3): 151–60
Fabregas JL, Claramunt J, Cucala J, et al. In vitro testing of an antacid formulation with prolonged gastric residence time (Almagate Flot-Coat). Drug Dev Ind Pharm 1994; (20): 1199–212
Washington N, Greaves JL, Wilson CG. Effect of time of dosing relative to a meal on the raft formation anti-reflux agent. J Pharm Pharmacol 1990; 42: 50–3
Chen J, Blevins WE, Park H, et al. Gastric retention properties of superporous hydrogel composites. J Control Rel 2000; 64: 39–51
Chen J, Park K. Synthesis and characterization of superporous hydrogel composites. J Control Rel 2000; 65 (1–2): 73–82
Park K. Superporous hydrogels for pharmaceutical and other applications. Drug Del Tech [online]. Available from URL: http://www.drugdeliverytech.com/cgi-bin/articles.cgi?.idArticle=60 [Accessed 2006 Mar 20]
Groning R, Werner M, Berntgen M, et al. Peroral controlled release dosage forms with internal magnets and extracorporeal magnetic guidance-investigations into the renal elimination of riboflavin. Eur J Pharm Biopharmacol 1996; 42: 25–8
Fujimori J, Machida Y, Tanaka S, et al. Effect of magnetically controlled gastric residence of sustained release tablets on bioavailability of acetaminophen. Int J Pharm 1995; 119: 47–55
Dong C, Rogers JA. Polymer-coated liposomes: stability and release of ASA from carboxymethyl chitin coated liposomes. J Control Rel 1991; 17: 217–24
Aamelu S, Rao KP. Studies on the carboxymethyl chitosan containing liposomes for their stability and controlled release of dapson. J Microencaps 1991; 8: 505–15
Takeuchi H, Yamamoto H, Niwa T, et al. Mucoadhesion of polymer-coated liposomes to rat intestine in vitro. Chem Pharm Bull 1994; 42: 1954–6
Arnold SC, Ferritto MS, Lenz RW, et al. pH dependent modification of phospholipid vesicle membrane by poly (carboxylic acid) bearing pendant cholesteryl esters. Polym Prepr 1986; 27: 42–3
Whitehead L, Fell JT, Collett JH, et al. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Rel 1998; 55 (1): 3–12
Patil JM, Hirlekar RS, Gide PS, et al. Trends in floating drug delivery systems. J Sci Ind Res 2006 Jan; 65: 11–21
Swarbrick J, Boylon JC. Encyclopedia of pharmaceutical technology. 2nd ed. Book 2. New York: Marcel Dekker, 2002: 1783–92
Hasim H, Li WPA. Improving the release characteristics of water-soluble drugs from hydrophilic sustained release matrices by in situ gas generation. Int J Pharm 1987; 35: 201–6
Chien YW. Controlled and modulated release drug delivery systems. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker, 1990: 280–313
Krogel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 1999; 187 (2): 175–84
Chen GL, Hao WH. In vitro performance of floating sustained release capsule of verapamil. Drug Dev Ind Pharm 1998; 24: 1067–72
Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 1987; 27 Suppl. 1: 21–7
Sheth PR, Tossounian J. The hydrodynamically balanced system: a novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 1984; 10 Suppl. 2: 313–39
Gerogiannis VS, Rekkas DM, Dallas PP, et al. Floating and swelling characteristics of various excipients used in controlled release technology. Drug Dev Ind Pharm 1993; 19: 1061–81
Streubel A, Siepmann J, Bodmeier R, et al. Floating microparticles based on low density foam powder. Int J Pharm 2002; 241 (2): 279–92
Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci 2003; 18 (1): 37–45
Sato Y, Kawashima Y, Takeuchi H, et al. In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery systems in healthy humans. Int J Pharm 2004; 275: 97–107
Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulgel gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur J Pharm Sci 2005; 24: 363–73
Samuel B, Philip A, Pathak K, et al. Preparation and evaluation of gastroretentive delivery system of flurbiprofen. Ind Pharm 2006; 45 (5): 77–9
Kawashima Y, Niwa T, Takeuchi H, et al. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992, 40
Jain SK, Jain NK, Agarwal GP. Floating delivery system, Gastroretentive floating drug delivery: an overview [online]. Drug Del Tech 2005 Jul/Aug; 5 (7). Available from URL: http://www.drugdeliverytech.com/cgi-bin/articles. cgi?.idArticle=400 [Accessed 2006 Jan 20]
Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Del Syst 1993; 10: 143–95
Timmermans J, Moes AJ. Measuring the resulting weight of an immersed test material: II. Examples of kinetic determinations applied for monolithic dosage forms. Acta Pharm Technol 1990; 36 (1): 176–80
Jain NK, Awasthi AM, Jain NK, et al. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. J Control Rel 2005; 107: 300–9
Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Del Rev 1998; 34: 191–219
Park K, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery: method to study bioadhesion. Int J Pharm 1984; 19 (2): 107–27
Peppas NA, Little MD, Yanbin H. Bioadhesive controlled release system. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, 2000: 255–70
Liu Z, Lu W, Qian L, et al. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Rel 2005; 102 (1): 135–44
Klausner EA, Lavy E, Stepensky D, et al. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res 2002; 19: 1516–23
Groning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur J Pharm Biopharm 1998; 46: 285–91
Pham AT, Lee PI. Probing the mechanism of drug release from hydroxy propyl- methyl cellulose metrics. Pharm Res 1994; 11: 1379–84
Klausner EA, Lavy E, Friedman M, et al. Expandable gastroretentive dosage forms. J Control Rel 2003; 90: 143–62
Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate. Int J Pharm 1992; 86 Suppl. 1: 79–88
Ronge N, Cole ET, Doelker E, et al. Buoyancy and drug release patterns of floating minitablets containing piretanide and atenolol as model drugs. Pharm Dev Technol 1998; 3 (1): 73–84
Pillay V, Fassihi R. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. J Control Rel 1998; 55 1: 45–55
Burns SJ, Attwood D, Barnwell SG. Assessment of the dissolution vessel designed for use with floating and erodible dosage form. Int J Pharm 1998; 160 (2): 213–8
British pharmacopoeia 1993. London: HMSO, 1993
Harland RS, Gazzaniga A, Sangalli ME, et al. Drug/polymer matrix swelling and dissolution. Pharm Res 1988; 5: 488–94
Xiaoquiang X, Minjie S, Feng Z, et al. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers. Int J Pharm 2006; 310: 139–45
Yang LB, Fassihi RA. Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. J Pharm Sci 1996; 85: 170–3
Sangekar S, Vadino WA, Chaudry I, et al. Evaluation of the effect of food and specific gravity of tablets on gastric retention time. Int J Pharm 1987; 35: 187–91
Joseph NJ, Lakshmi S, Jayakrishnan A. A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits. J Control Rel 2002; 79: 71–9
Chavanpatil M, Jain P, Chaudhari S, et al. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int J Pharm 2005; 304: 178–84
Mojaverian I, Chan K, Desai A. Gastrointestinal transit of a solid indigestible capsule as measured by radiotelemetry and dual gamma scintigraphy. Pharm Res 1989; 6: 719–24
Fell JT, Digenis GA. Imaging and behaviour of solid oral dosage forms in vivo. Int J Pharm 1984; 22 (1): 1–15
Ingani HM, Timmermans J, Moes AJ. Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit. Int J Pharm 1987; 35: 157–64
Philip AK, Pathak K. Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility [online]. AAPS Pharm-SciTech 2006 Jul 7; Suppl. 3: Article 56. Available from URL: http://www.aap-spharmscitech.org/view.asp?art=pt070356 [Accessed 2006 July 8]
Gupta SK. Stability studies of ampicillin floating tablets (Ampiflot) and buffered ampiflot [masters thesis]. New York: St John’s University, 1987
Kulkarni GT, Gowthamarajan K, Suresh B. Stability testing of pharmaceutical products: an overview. Ind J Pharm Edu Res 2004; 38 (4): 194–202
Stability testing guidelines: stability testing of new drug substances and products [online]. Available from URL: http://www.emea.eu.int [Accessed 2005 Jul 8]
O’Laughlin JC, Hoffiezer JW, Ivery KJ. Effect of aspirin on the stomach in normals: endoscopic comparison of damage produced one hour, 24 hours and 2 weeks after administration. Scand J Gastroenterol 1981; 16 Suppl. 67: 211–4
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kumar, R., Philip, A. Gastroretentive Dosage Forms for Prolonging Gastric Residence Time. Int J Pharm Med 21, 157–171 (2007). https://doi.org/10.2165/00124363-200721020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00124363-200721020-00005